GB9710351D0 - Glucosamine fatty acids - Google Patents

Glucosamine fatty acids

Info

Publication number
GB9710351D0
GB9710351D0 GBGB9710351.9A GB9710351A GB9710351D0 GB 9710351 D0 GB9710351 D0 GB 9710351D0 GB 9710351 A GB9710351 A GB 9710351A GB 9710351 D0 GB9710351 D0 GB 9710351D0
Authority
GB
United Kingdom
Prior art keywords
fatty acids
glucosamine fatty
glucosamine
acids
fatty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9710351.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scotia Holdings PLC
Original Assignee
Scotia Holdings PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings PLC filed Critical Scotia Holdings PLC
Priority to GBGB9710351.9A priority Critical patent/GB9710351D0/en
Publication of GB9710351D0 publication Critical patent/GB9710351D0/en
Priority to EP98921639A priority patent/EP0977561A1/en
Priority to PCT/GB1998/001425 priority patent/WO1998052556A1/en
Priority to CA002290488A priority patent/CA2290488A1/en
Priority to AU74423/98A priority patent/AU7442398A/en
Priority to ZA984211A priority patent/ZA984211B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
GBGB9710351.9A 1997-05-20 1997-05-20 Glucosamine fatty acids Ceased GB9710351D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB9710351.9A GB9710351D0 (en) 1997-05-20 1997-05-20 Glucosamine fatty acids
EP98921639A EP0977561A1 (en) 1997-05-20 1998-05-18 Glucosamine fatty acid compositions and their use
PCT/GB1998/001425 WO1998052556A1 (en) 1997-05-20 1998-05-18 Glucosamine fatty acid compositions and their use
CA002290488A CA2290488A1 (en) 1997-05-20 1998-05-18 Glucosamine fatty acid compositions and their use
AU74423/98A AU7442398A (en) 1997-05-20 1998-05-18 Glucosamine fatty acid compositions and their use
ZA984211A ZA984211B (en) 1997-05-20 1998-05-19 Glucosamine fatty acids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9710351.9A GB9710351D0 (en) 1997-05-20 1997-05-20 Glucosamine fatty acids

Publications (1)

Publication Number Publication Date
GB9710351D0 true GB9710351D0 (en) 1997-07-16

Family

ID=10812725

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9710351.9A Ceased GB9710351D0 (en) 1997-05-20 1997-05-20 Glucosamine fatty acids

Country Status (6)

Country Link
EP (1) EP0977561A1 (en)
AU (1) AU7442398A (en)
CA (1) CA2290488A1 (en)
GB (1) GB9710351D0 (en)
WO (1) WO1998052556A1 (en)
ZA (1) ZA984211B (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214666B1 (en) 1999-11-02 2007-05-08 Shawn Paul Madere Composition of orally administered nutritional supplements to repair articular cartilage
DE60035227D1 (en) * 1999-11-02 2007-07-26 Shawn Paul Madere ORAL PREPARATIONS FOR THE SUPPLY OF FOODSTUFFS TO CURE PILLARS
DE10019255A1 (en) * 2000-04-18 2001-10-31 Henkel Kgaa Glycoside esters and their production and use in cosmetics, pharmaceuticals and food or feed
WO2004032824A2 (en) 2002-10-10 2004-04-22 Yeda Research And Development Co. Ltd. Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
CA2641510A1 (en) * 2006-02-07 2007-08-16 Pal Rongved Omega 3
DE102007055344A1 (en) 2007-11-19 2009-05-20 K. D. Pharma Bexbach Gmbh New use of omega-3 fatty acid (s)
FR2940281B1 (en) * 2008-12-22 2011-04-01 Fabre Pierre Dermo Cosmetique ESTER OF DIOL AND POLYUNSATURATED FATTY ACID AS ANTI-ACNE AGENT
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
RU2013133998A (en) * 2010-12-21 2015-01-27 Нестек С.А. METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF OSTEOARTHRITIS
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
SG11201407300VA (en) 2012-05-07 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of neurological disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
AU2013257742A1 (en) 2012-05-07 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US20150148306A1 (en) * 2012-05-08 2015-05-28 Mahesh Kandula Compositions and methods for the treatment of inflammation
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013175359A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175377A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
EP2892878A4 (en) 2012-09-08 2016-02-24 Cellix Bio Private Ltd Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (en) 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
US9682055B2 (en) 2014-06-04 2017-06-20 Dignity Sciences Limted Pharmaceutical compositions comprising DGLA and use of same
NZ736131A (en) 2014-09-26 2019-04-26 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
CA2967908C (en) 2014-09-29 2020-11-17 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
AU2014414316B2 (en) 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN110845355A (en) 2015-01-06 2020-02-28 塞尔利克斯生物私人有限公司 Compositions and methods for treating inflammation and pain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5939813A (en) * 1982-08-26 1984-03-05 Shiseido Co Ltd Cosmetic
JPH07507312A (en) * 1992-05-26 1995-08-10 アルバータ　リサーチ　カウンスル Reduction of inflammation by time-dependent administration of oligosaccharide glycosides related to blood type determinants
GB9413935D0 (en) * 1994-07-11 1994-08-31 Peptech Uk Ltd Use of maramyl peptide compounds
US5639787A (en) * 1995-02-28 1997-06-17 The Center For The Improvement Of Human Functioning Int'l, Inc. Therapeutic method for the treatment of cancer
GB9508023D0 (en) * 1995-04-20 1995-06-07 Scotia Holdings Plc Fatty acid derivatives
EP0855908B1 (en) * 1995-12-11 2002-02-06 Omni Nutraceuticals, Inc. Dietary regimen of nutritional supplements for relief of symptoms of arthritis

Also Published As

Publication number Publication date
EP0977561A1 (en) 2000-02-09
WO1998052556A1 (en) 1998-11-26
CA2290488A1 (en) 1998-11-26
ZA984211B (en) 1998-11-20
AU7442398A (en) 1998-12-11

Similar Documents

Publication Publication Date Title
ZA984211B (en) Glucosamine fatty acids
HU9801045D0 (en) Substituted diamino-carboxylic acids
HUP0101672A3 (en) Substituted indolealkanoic acids
ZA951661B (en) Fatty acid derivatives
AU6482398A (en) Sulfonylaminocarboxylic acids
AU5470299A (en) Fatty ester combinations
TW371531U (en) High speed connector
HUP0000937A3 (en) New fatty acid derivatives
GB2328251B (en) Propeller
EP0801644A4 (en) Polyarylcarbamoylaza -and- carbamoylalkanedioic acids
GB9508023D0 (en) Fatty acid derivatives
EP0986296A4 (en) Fatty acid elongases
ZA952008B (en) 5-vinyl- and 5-ethinyl-quinolene- and -naphthyridone- carboxylic acids
GB9706281D0 (en) Ester co-production
PL332553A1 (en) 3-alkooxyisooxazol-4-yl-substituted 2-aminocarboxylic acids
GB9420010D0 (en) Nucleic acids
GB9812674D0 (en) Nucleic acids
IL129500A0 (en) Fatty acid derivatives II
GB2333525B (en) Esterification process
HUP9901345A3 (en) Novel quinoxaline- and quinoxalinylalkane-phosphonic acids
GB9408064D0 (en) Nucleic acids
GB9700383D0 (en) Fatty acid treatent
ZA977376B (en) Propeller
AU3645195A (en) Modified polyunsaturated fatty acids
GB9720995D0 (en) Nucleic acids

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)